Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · Real-Time Price · USD
0.360
-0.012 (-3.28%)
Dec 20, 2024, 4:00 PM EST - Market closed
Organovo Holdings Employees
As of March 31, 2024, Organovo Holdings had 20 total employees, including 12 full-time and 8 part-time employees. The number of employees decreased by 4 or -16.67% compared to the previous year.
Employees
20
Change (1Y)
-4
Growth (1Y)
-16.67%
Revenue / Employee
$5,150
Profits / Employee
-$627,100
Market Cap
5.53M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IM Cannabis | 95 |
| Syros Pharmaceuticals | 68 |
| Intelligent Bio Solutions | 50 |
| Evaxion Biotech | 49 |
| Sunshine Biopharma | 44 |
| Quantum BioPharma | 17 |
| Bio-Path Holdings | 10 |
| Hoth Therapeutics | 3 |
ONVO News
- 4 weeks ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire
- 5 weeks ago - Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - GlobeNewsWire
- 5 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 5 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 7 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 7 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 8 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 8 months ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters